GlassScriptPhysician profile
Steven P Marshak
NPI 1730110305
$5,801.52
in general payments reported to CMS, 2019-2025
45 companies · $988 in 2025
The $988 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $747 · 2020: $669 · 2021: $781 · 2022: $851 · 2023: $805 · 2024: $961 · 2025: $988.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,753.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,753.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $952.73 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $738.51 | 2019-2025 | |
| Ironshore Pharmaceuticals INC. | $412.44 | 2019-2024 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $400.27 | 2019-2022 | |
| Pfizer INC. | $375.03 | 2019-2024 | |
| Lilly USA, LLC | $318.96 | 2020-2025 | Mounjaro, Zepbound, Emgality |
| Merck Sharp & Dohme LLC | $215.24 | 2019-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Adlon Therapeutics L.P. | $171.44 | 2019-2021 | |
| Glaxosmithkline, LLC. | $169.01 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Gilead Sciences, INC. | $161.78 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $157.42 | 2019-2023 | Farxiga |
| Biohaven Pharmaceutical Holding Company LTD. | $140.08 | 2022 | |
| Exact Sciences Corporation | $121.24 | 2023-2024 | Cologuard Collection Kit |
| Abbott Laboratories | $108.67 | 2021-2024 | Freestyle Libre 3 |
| Collegium Pharmaceutical, INC. | $105.75 | 2025 | Jornay Pm |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Marshak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.